In vitro and ex vivo complement functional assays plus in vivo complement inhibition in monkey
“Avacincaptad pegol has demonstrated complement inhibitory activity in several in vitro and ex vivo functional assays and in vivo in the monkey.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Why that model
Human C5-specific aptamer: monkey has 1/10th and rat 1/1000th of activity against human C5
“The monkey is the only species identified that could be considered relevant showing 1/10th of the ARC1905 in an in vitro activity assay against human C5. The rat has 1/1000th of the in vitro activity against human C5.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Reviewer's view of the efficacy data
FDA: monkey data imply ~10 µg/mL needed for complete C5 inhibition; clinical Cmax 68.3 ng/mL is over 140x lower
“Based on this fact, it seems we can assume plasma concentrations of approximately 10 μg/mL will be required in humans for complete C5 inhibition. The clinical Cmax was 68.3 ng/mL, over 140X lower than the estimated concentration for complete C5 inhibition.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗